Evidence map›Paper›PMID 19377516›Full record

ArticleBone marrow transplantation2009

Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors.

X-Y Zhao, Y-J Chang, L-P Xu, D-H Liu, K-Y Liu, X-J Huang

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

X-Y ZhaoDepartment of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology, Peking University People's Hospital, no. 11 Xizhimen South Street, Beijing, China.
Y-J Chang
L-P Xu
D-H Liu
K-Y Liu
X-J Huang
Peking University People's Hospital · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate the effects of natural killer (NK) cells on transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors. Forty-one haploidentical allogeneic hematopoietic SCT patients were analyzed according to the NK cell concentration in relation to acute GVHD (aGVHD), chronic GVHD (cGVHD), TRM and leukemia-free survival. The patients receiving a higher dose of CD56(bright) NK cells (>1.9 x 10(6)/kg) showed a higher incidence of grades II-IV aGVHD (hazard risk (HR), 2.872; P=0.022) and cGVHD (HR, 2.884; P=0.039). A higher CD56(dim)/CD56(bri) NK cell ratio (>8.0) was correlated with a decreased risk of III-IV aGVHD (HR, 0.290; P=0.065) and TRM (HR, 0.072; P=0.012), thereby increasing the rate of leukemia-free survival (HR, 0.174; P=0.007) after haploidentical transplantation without in vitro T-cell depletion. Our results suggest that a high allograft CD56(dim)/CD56(bright) NK cell ratio (>8.0) plays an important role in improving transplant outcomes. A higher dose of CD56(bright) NK cells might be a predictor for a higher incidence of GVHD.

Indexed as

AdultBone Marrow CellsCD56 AntigenDisease-Free SurvivalFemaleGraft vs Host DiseaseGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHistocompatibility TestingHLA AntigensHumansKiller Cells, NaturalMaleTissue DonorsTransplantation ConditioningCD56 AntigenGranulocyte Colony-Stimulating FactorHLA Antigens

Identifiers

PMID19377516
OpenAlexW1997724344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.